One of Asia-Pacific’s largest regional contract research organizations (CRO) called Novotech, reports that many countries are fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment and vaccine candidates. In fact, Novotech reports another COVID-19 trial was just approved in under 9 days in South Korea—these study launch times are shattering the record books. The South Korean Ministry of Food and Drug Safety (MFDS) announced “Go-expedite”, a program expediting COVID-19 clinical trial review timelines.
Studies launched in record time across Asia
According to a recent press release published in EurekAlert!, the following countries are experiencing rapid acceleration of COVID-19 clinical trial reviews:
· India: review/approval in 10 working days
· Thailand: review/approval in 15 working days
· Malaysia: review/approval in 20 working days
Dr. Yooni Kim, the Executive Director for Asia Operations of Novotech, reports that the regional rapid response represents an ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).